Canadian Anaplastic Lymphoma Kinase Study: A Model for Multicenter Standardization and Optimization of ALK Testing in Lung Cancer

Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

Manabu Soda, Young Lim Choi, Munehiro Enomoto et al. · Nature · 2007 · 5.4K citations

Medicine, Molecular Biology, Oncology +14

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa et al. · New England Journal of Medicine · 2013 · 3.4K citations · Full text

Medicine, Oncology, Pharmacology +15

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

Neal I. Lindeman, Philip T. Cagle, Mary Beth Beasley et al. · Journal of Thoracic Oncology · 2013 · 1.3K citations · Full text

Medicine, Molecular Medicine, Oncology +17

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

D. Ross Camidge, Yung‐Jue Bang, Eunice L. Kwak et al. · The Lancet Oncology · 2012 · 1.3K citations

Medicine, Oncology, Pharmacology +15

Unique Clinicopathologic Features Characterize <i>ALK</i> -Rearranged Lung Adenocarcinoma in the Western Population

Scott J. Rodig, Mari Mino–Kenudson, Beow Y. Yeap et al. · Clinical Cancer Research · 2009 · 682 citations · Full text

Medicine, Oncology, Pathology +17